NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
TORONTO and HAIFA, Israel, June 28, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB:NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce a pre-clinical study to explore the potential of NurExone’s exosome-based therapies in regenerating damaged optic nerves. The study, initiated by renowned ophthalmologist and serial entrepreneur Prof. Michael Belkin from Tel Aviv University’s Goldschleger Eye Research Institute, and led by the principal investigators Prof. Ygal Rotenstreich and Dr. Ifat Sher from the Sheba Medical Center Eye Institute1, is the latest step in expanding potential clinical indications for Nurexone Biologic’s exosome-loaded drugs.
Related news for (NRXBF)
- NurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update
- NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
- NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement
- NurExone Biologic Recognized as a 2025 TSX Venture 50(TM) Top Performing Stock
- NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award